166 related articles for article (PubMed ID: 33089889)
21. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
22. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 in breast cancer: oncogenic role and therapeutic targeting.
Xu C; Zhao H; Chen H; Yao Q
Drug Des Devel Ther; 2015; 9():4953-64. PubMed ID: 26356032
[TBL] [Abstract][Full Text] [Related]
24. A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea.
Hersh TA; Dimond AL; Ruth BA; Lupica NV; Bruce JC; Kelley JM; King BL; Lutton BV
Am J Physiol Regul Integr Comp Physiol; 2018 Aug; 315(2):R218-R229. PubMed ID: 29641231
[TBL] [Abstract][Full Text] [Related]
25. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
26. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
27. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
28. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
29. The CXCL12-CXCR4 Signaling Axis Plays a Key Role in Cancer Metastasis and is a Potential Target for Developing Novel Therapeutics against Metastatic Cancer.
Yang P; Hu Y; Zhou Q
Curr Med Chem; 2020; 27(33):5543-5561. PubMed ID: 31724498
[TBL] [Abstract][Full Text] [Related]
30. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.
Weitzenfeld P; Ben-Baruch A
Cancer Lett; 2014 Sep; 352(1):36-53. PubMed ID: 24141062
[TBL] [Abstract][Full Text] [Related]
31. Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors.
Liu N; Wan Q; Cheng Z; Chen Y
Curr Top Med Chem; 2019; 19(1):17-32. PubMed ID: 30706786
[TBL] [Abstract][Full Text] [Related]
32. [Clinical relevance of chemokine receptor CXCR4].
Gębura K; Bogunia-Kubik K
Postepy Hig Med Dosw (Online); 2012 May; 66():252-66. PubMed ID: 22706111
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
34. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
35. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
Terasaki M; Sugita Y; Arakawa F; Okada Y; Ohshima K; Shigemori M
Brain Tumor Pathol; 2011 Apr; 28(2):89-97. PubMed ID: 21210239
[TBL] [Abstract][Full Text] [Related]
36. CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.
Mortezaee K
Life Sci; 2020 May; 249():117534. PubMed ID: 32156548
[TBL] [Abstract][Full Text] [Related]
37. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
Suzuki K; Ui T; Nagano A; Hino A; Arano Y
Sci Rep; 2019 Oct; 9(1):15284. PubMed ID: 31653903
[TBL] [Abstract][Full Text] [Related]
38. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
40. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
